1
|
Dote S, Shiwaku E, Kohno E, Fujii R, Mashimo K, Morimoto N, Yoshino M, Odaira N, Ikesue H, Hirabatake M, Takahashi K, Takahashi M, Takagi M, Nishiuma S, Ito K, Shimato A, Itakura S, Takahashi Y, Negoro Y, Shigemori M, Watanabe H, Hayasaka D, Nakao M, Tasaka M, Goto E, Kataoka N, Yokomizo A, Kobayashi A, Nakata Y, Miyake M, Hayashi Y, Yamamoto Y, Hirata T, Azuma K, Makihara K, Fukui R, Tokutome A, Yagisawa K, Honda S, Meguro Y, Suzuki S, Yamaguchi D, Miyata H, Kobayashi Y. Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study. Int J Clin Oncol 2023:10.1007/s10147-023-02357-3. [PMID: 37261583 PMCID: PMC10233195 DOI: 10.1007/s10147-023-02357-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Accepted: 05/18/2023] [Indexed: 06/02/2023]
Abstract
BACKGROUND The association between prior bevacizumab (BEV) therapy and ramucirumab (RAM)-induced proteinuria is not known. We aimed to investigate this association in patients with metastatic colorectal cancer (mCRC). METHODS mCRC patients who received folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus RAM were divided into with and without prior BEV treatment groups. The cumulative incidence of grade 2-3 proteinuria and rate of RAM discontinuation within 6 months (6M) after RAM initiation were compared between the two groups. RESULTS We evaluated 245 patients. In the Fine-Gray subdistribution hazard model including prior BEV, age, sex, comorbidities, eGFR, proteinuria ≥ 2 + at baseline, and later line of RAM, prior BEV treatment contributed to proteinuria onset (P < 0.01). A shorter interval between final BEV and initial RAM increased the proteinuria risk; the adjusted odds ratios (95% confidence intervals) for the intervals of < 28 days, 28-55 days, and > 55 days (referring to prior BEV absence) were 2.60 (1.23-5.51), 1.51 (1.01-2.27), and 1.04 (0.76-1.44), respectively. The rate of RAM discontinuation for ≤ 6M due to anti-VEGF toxicities was significantly higher in the prior BEV treatment group compared with that in the no prior BEV treatment group (18% vs. 6%, P = 0.02). Second-line RAM discontinuation for ≤ 6M without progression resulted in shorter overall survival of 132 patients with prior BEV treatment (P < 0.01). CONCLUSION Sequential FOLFIRI plus RAM after BEV failure, especially within 55 days, may exacerbate proteinuria. Its escalated anti-VEGF toxicity may negatively impact the overall survival.
Collapse
Affiliation(s)
- Satoshi Dote
- Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan.
| | - Eiji Shiwaku
- Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan
| | - Emiko Kohno
- Department of Pharmacy, Kansai Medical University Hospital, Osaka, Japan
| | - Ryohei Fujii
- Department of Pharmacy, Kansai Medical University Hospital, Osaka, Japan
| | - Keiji Mashimo
- Department of Pharmacy, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | - Naomi Morimoto
- Department of Pharmacy, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | - Masaki Yoshino
- Department of Pharmacy, Niigata Cancer Center Hospital, Niigata, Japan
| | - Naoki Odaira
- Department of Pharmacy, Niigata Cancer Center Hospital, Niigata, Japan
| | - Hiroaki Ikesue
- Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan
| | - Masaki Hirabatake
- Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan
| | | | - Masaya Takahashi
- Department of Pharmacy, Osaka City University Hospital, Osaka, Japan
| | - Mari Takagi
- Department of Pharmacy, Osaka International Cancer Institute, Osaka, Japan
| | - Satoshi Nishiuma
- Department of Pharmacy, Osaka International Cancer Institute, Osaka, Japan
| | - Kaori Ito
- Department of Clinical Pharmacy, School of Medicine, Fujita Health University, Aichi, Japan
| | - Akane Shimato
- Department of Clinical Pharmacy, School of Medicine, Fujita Health University, Aichi, Japan
| | - Shoji Itakura
- Department of Pharmacy, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
| | - Yoshitaka Takahashi
- Department of Pharmacy, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
| | - Yutaka Negoro
- Department of Pharmacy, University of Fukui Hospital, Fukui, Japan
| | - Mina Shigemori
- Department of Pharmacy, University of Fukui Hospital, Fukui, Japan
| | | | - Dai Hayasaka
- Department of Pharmacy, Matsushita Memorial Hospital, Osaka, Japan
| | - Masahiko Nakao
- Department of Pharmacy, Osaka City General Hospital, Osaka, Japan
| | - Misaki Tasaka
- Department of Pharmacy, Osaka City General Hospital, Osaka, Japan
| | - Emi Goto
- Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan
| | - Noriaki Kataoka
- Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan
| | - Ayako Yokomizo
- Department of Pharmacy, St. Marianna University Hospital, Kanagawa, Japan
| | - Ayako Kobayashi
- Department of Pharmacy, St. Marianna University Hospital, Kanagawa, Japan
| | - Yoko Nakata
- Department of Pharmacy, Medical Research Institute KITANO HOSPITAL, Osaka, Japan
| | - Mafumi Miyake
- Department of Pharmacy, Medical Research Institute KITANO HOSPITAL, Osaka, Japan
| | - Yaeko Hayashi
- Department of Pharmacy, Omihachiman Community Medical Center, Shiga, Japan
| | - Yoshie Yamamoto
- Department of Pharmacy, Omihachiman Community Medical Center, Shiga, Japan
| | - Taiki Hirata
- Department of Pharmacy, Tokyo Medical University Hospital, Tokyo, Japan
| | - Kanako Azuma
- Department of Pharmacy, Tokyo Medical University Hospital, Tokyo, Japan
| | - Katsuya Makihara
- Department of Pharmacy, Yodogawa Christian Hospital, Osaka, Japan
| | - Rino Fukui
- Department of Pharmacy, Yodogawa Christian Hospital, Osaka, Japan
| | - Akira Tokutome
- Department of Pharmacy, Sapporo-Higashi Tokushukai General Hospital/Institute of Biomedical Research, Hokkaido, Japan
| | - Keiji Yagisawa
- Department of Pharmacy, Sapporo-Higashi Tokushukai General Hospital/Institute of Biomedical Research, Hokkaido, Japan
| | - Shinji Honda
- Department of Pharmacy, Kyoto City Hospital, Kyoto, Japan
| | - Yuji Meguro
- Department of Pharmacy, Kyoto City Hospital, Kyoto, Japan
| | - Shota Suzuki
- Institute for Clinical and Translational Science, Nara Medical University Hospital, Nara, Japan
| | - Daisuke Yamaguchi
- Department of Medical Oncology, Kyoto-Katsura Hospital, Kyoto, Japan
| | - Hitomi Miyata
- Department of Nephrology, Kyoto-Katsura Hospital, Kyoto, Japan
| | - Yuka Kobayashi
- Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan
| |
Collapse
|
2
|
Saito Y, Tamaki S, Hasegawa H, Takahashi K, Tokutome A, Takekuma Y, Yamashita H, Komatsu Y, Sugawara M. Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study. Biol Pharm Bull 2021; 44:474-477. [PMID: 33790098 DOI: 10.1248/bpb.b20-00984] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
CT-P6 is a biosimilar of trastuzumab and is recommended to be administered for 30-90 min in subsequent maintenance infusions to prevent infusion-related reactions (IRRs). We administered CT-P6 for 30 min as the first injection and as an alternative to reference trastuzumab in the maintenance infusion and evaluated the safety of the administration. A total of 140 patients with breast or gastric cancer, who received a switch from tri-weekly reference trastuzumab to CT-P6 for 30 min in maintenance infusions, were retrospectively evaluated. Premedication was administered prior to an infusion of CT-P6 and a cytotoxic agent. However, premedication was not provided when CT-P6 was co-administered with pertuzumab or administered alone. The primary endpoint was the incidence of IRRs. The secondary endpoint was the incidence of diarrhea and skin toxicity. Ninety-five percent of the patients had breast cancer, and 44.3% had advance-stage cancer. The treatment included CT-P6 alone (17.9%) or with cytotoxic agents (23.6%), antihormonal drugs (25.7%), and pertuzumab (62.9%). Median administration time of trastuzumab at the switch was 13 administrations (range 2-140). Premedication was administered to 20.7% patients. One patient (0.7%) experienced grade 3 IRR. The frequency of diarrhea in the reference trastuzumab group and the CT-P6 group was 7.1 and 6.4%, respectively, and that of skin toxicity was 6.4 and 5.0%, respectively, without differences. In conclusion, we first demonstrated that an initial CT-P6 administration for 30 min during the switch from reference trastuzumab in maintenance infusion is an acceptable administration method.
Collapse
Affiliation(s)
| | | | - Haruka Hasegawa
- Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center
| | | | - Akira Tokutome
- Department of Pharmacy, Sapporo Higashi Tokushukai General Hospital
| | - Yoh Takekuma
- Department of Pharmacy, Hokkaido University Hospital
| | | | | | - Mitsuru Sugawara
- Department of Pharmacy, Hokkaido University Hospital.,Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University
| |
Collapse
|